SOPHiA GENETICS Reports Second Quarter 2026 Results
SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2026 revenue of $23.3 million, up 27% year over year, with gross margin of 64.6% reported and 72.1% adjusted. Net loss was $22.4 million and adjusted EBITDA loss was $8.8 million, improving 27%. The company raised 2026 revenue guidance to $94-$96 million and signed AstraZeneca companion diagnostic programs.
How this was made
The 30-second read
Why it matters
The key trading signal is the combination of Q2 operating progress (improving adjusted EBITDA loss) and an increased FY 2026 revenue outlook, supported by a fresh $57.5M oversubscribed public offering that extends the cash runway.
Market read
This is a primary earnings-and-guidance update with a capital raise, likely driving repricing of FY growth expectations and near-term risk around funding needs.
What to watch
The article emphasizes adjusted metrics and volume growth; traders may want to scrutinize cash burn trajectory, implementation timelines for signed customers, and whether gross margin expansion is sustainable.
Background
SOPHiA GENETICS is an AI-driven precision medicine company monetizing genomic analyses and applications such as liquid biopsy and solid tumor workflows.
Ticker impact
SOPHiA GENETICS reported Q2 revenue of $23.3M (+27% YoY) and raised 2026 revenue guidance to $94M-$96M.
Near-term upside bias as traders reprice FY growth and cash runway after the oversubscribed $57.5M offering.
The article discloses fresh, decision-relevant datapoints: Q2 results, updated FY revenue range, and capital raised to fund growth, all tied to SOPH’s own outlook.
Market effects
Precision medicine and companion diagnostic ecosystem may see incremental confidence in AI-enabled genomics workflows and CDx commercialization momentum.
US growth and liquid biopsy traction highlight demand strength in North America, potentially influencing sentiment toward similar US-listed precision medicine names.
AstraZeneca CDx companion diagnostic programs and multi-country customer wins reinforce cross-border adoption of SOPHiA’s platform.
Counterpoint
Despite revenue growth, the company still reports a large net loss and adjusted EBITDA loss, so the guidance raise may not yet translate into profitability credibility.
Key entities
- public_companySOPHiA GENETICS
Nasdaq-listed precision medicine company reporting Q2 2026 results and raising FY 2026 revenue guidance.
- public_companyAstraZeneca
Partnered with SOPHiA on two companion diagnostic programs announced in the quarter.
